Georges Doumet HELOU

Dr. Georges Doumet HELOU

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
GHGeorges Doumet HELOU
Georges Doumet HELOU
PSPedram Shafiei-Jahani
Pedram Shafiei-Jahani
RLRichard Lo
Richard Lo
EHEmily Howard
Emily Howard
BHBenjamin P. Hurrell
Benjamin P. Hurrell
OAOmid Akbari
Omid Akbari
Allergic asthma is a leading chronic disease associated with airway hyperreactivity (AHR). Type-2 innate lymphoid cells (ILC2s) are a potent source of T-helper 2 (Th2) cytokines that promote AHR and lung inflammation. As the programmed cell death protein-1 (PD-1) inhibitory axis regulates a variety of immune responses, here we investigate PD-1 function in pulmonary ILC2s during IL-33-induced airway inflammation. PD-1 limits the viability of ILC2s and downregulates their effector functions. Additionally, PD-1 deficiency shifts ILC2 metabolism toward glycolysis, glutaminolysis and methionine catabolism. PD-1 thus acts as a metabolic checkpoint in ILC2s, affecting cellular activation and proliferation. As the blockade of PD-1 exacerbates AHR, we also develop a human PD-1 agonist and show that it can ameliorate AHR and suppresses lung inflammation in a humanized mouse model. Together, these results highlight the importance of PD-1 agonistic treatment in allergic asthma and underscore its therapeutic potential.

18 September 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
GLGavin Lewis
Gavin Lewis
BWBowen Wang
Bowen Wang
PJPedram Shafiei Jahani
Pedram Shafiei Jahani
BHBenjamin P. Hurrell
Benjamin P. Hurrell
HBHomayon Banie
Homayon Banie
OAOmid Akbari
Omid Akbari
Group 2 Innate lymphoid cells (ILC2) contribute significantly to allergic inflammation. However, the role of microbiota on ILC2s remains to be unraveled. Here we show that short chain fatty acids (SCFAs), such as butyrate, derived from fermentation of dietary fibers by the gut microbiota inhibit pulmonary ILC2 functions and subsequent development of airway hyperreactivity (AHR). We further show that SCFAs modulate GATA3, oxidative phosphorylation, and glycolytic metabolic pathways in pulmonary ILC2s. The observed phenotype is associated with increased IL-17a secretion by lung ILC2s and linked to enhanced neutrophil recruitment to the airways. Finally, we show that butyrate-producing gut bacteria in germ-free mice effectively suppress ILC2-driven AHR. Collectively, our results demonstrate a previously unrecognized role for microbial-derived SCFAs on pulmonary ILC2s in the context of AHR. The data suggest strategies aimed at modulating metabolomics and microbiota in the gut, not only to treat, but to prevent lung inflammation and asthma.

7 May 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
GHGeorges Doumet HELOU
Georges Doumet HELOU
SMStefan F. Martin
Stefan F. Martin
MPMarc Pallardy
Marc Pallardy
SCSylvie Chollet-Martin
Sylvie Chollet-Martin
SKSaadia Kerdine-Römer
Saadia Kerdine-Römer
Exposure to certain chemicals disturbs skin homeostasis. In particular, protein-reactive chemical contact sensitizers trigger an inflammatory immune response resulting in eczema and allergic contact dermatitis. Chemical sensitizers activate innate immune cells which orchestrate the skin immune response. This involves oxidative and inflammatory pathways. In parallel, the Nrf2/Keap1 pathway, a major ubiquitous regulator of cellular oxidative and electrophilic stress is activated in the different skin innate immune cells including epidermal Langerhans cells and dermal dendritic cells, but also in keratinocytes. In this context, Nrf2 shows a strong protective capacity through the downregulation of both the oxidative stress and inflammatory pathways. In this review we highlight the important role of Nrf2 in the control of the innate immune response of the skin to chemical sensitizers.

1 April 2021 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
EHEmily Howard
Emily Howard
GLGavin Lewis
Gavin Lewis
LGLauriane Galle-Treger
Lauriane Galle-Treger
BHBenjamin P. Hurrell
Benjamin P. Hurrell
GHGeorges Doumet HELOU
Georges Doumet HELOU
OAOmid Akbari
Omid Akbari

1 December 2019 in Cell Reports
Verified
Journal Article
Open access
BHBenjamin P. Hurrell
Benjamin P. Hurrell
LGLauriane Galle-Treger
Lauriane Galle-Treger
PJPedram Shafiei Jahani
Pedram Shafiei Jahani
EHEmily Howard
Emily Howard
GHGeorges Doumet HELOU
Georges Doumet HELOU
OAOmid Akbari
Omid Akbari
Group 2 innate lymphoid cells (ILC2s) can initiate pathologic inflammation in allergic asthma by secreting copious amounts of type 2 cytokines, promoting lung eosinophilia and airway hyperreactivity (AHR), a cardinal feature of asthma. We discovered that the TNF/TNFR2 axis is a central immune checkpoint in murine and human ILC2s. ILC2s selectively express TNFR2, and blocking the TNF/TNFR2 axis inhibits survival and cytokine production and reduces ILC2-dependent AHR. The mechanism of action of TNFR2 in ILC2s is through the non-canonical NF-κB pathway as an NF-κB-inducing kinase (NIK) inhibitor blocks the costimulatory effect of TNF-α. Similarly, human ILC2s selectively express TNFR2, and using hILC2s, we show that TNFR2 engagement promotes AHR through a NIK-dependent pathway in alymphoid murine recipients. These findings highlight the role of the TNF/TNFR2 axis in pulmonary ILC2s, suggesting that targeting TNFR2 or relevant signaling is a different strategy for treating patients with ILC2-dependent asthma.

5 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
PSPedram Shafiei-Jahani
Pedram Shafiei-Jahani
GHGeorges Doumet HELOU
Georges Doumet HELOU
BHBenjamin P. Hurrell
Benjamin P. Hurrell
EHEmily Howard
Emily Howard
CQChristine Quach
Christine Quach
OAOmid Akbari
Omid Akbari
The prevalence of asthma and airway hyperreactivity (AHR) is increasing at an alarming rate. Group 2 innate lymphoid cells (ILC2s) are copious producers of type 2 cytokines, which leads to AHR and lung inflammation. Here, we show that mouse ILC2s express CD200 receptor (CD200R) and this expression is inducible. CD200R engagement inhibits activation, proliferation and type 2 cytokine production, indicating an immunoregulatory function for the CD200–CD200R axis on ILC2s. Furthermore, CD200R engagement inhibits both canonical and non-canonical NF-κB signaling pathways in activated ILC2s. Additionally, we demonstrate both preventative and therapeutic approaches utilizing CD200R engagement on ILC2s, which lead to improved airway resistance, dynamic compliance and eosinophilia. These results show CD200R is expressed on human ILC2s, and its engagement ameliorates AHR in humanized mouse models, emphasizing the translational applications for treatment of ILC2-related diseases such as allergic asthma.